Abstract
A novel imidazo-pyramidazine inhibitor of DAPK1 that undergoes class-specific interactions and extends into the substrate recognition site has been identified. This inhibitor is a good starting point for the development of selective and potent inhibitors of DAPK1, with potential use against stroke and ischemia.
Original language | English |
---|---|
Journal | ChemBioChem |
Volume | 16 |
Issue number | 1 |
Pages (from-to) | 59-63 |
Number of pages | 5 |
ISSN | 1439-4227 |
DOIs | |
Publication status | Published - 2 Jan 2015 |